Airway response to respiratory syncytial virus has incidental antibacterial effects

ABSTRACT

Nat Commun

RSV infection is typically associated with secondary bacterial infection. We hypothesise that the local airway immune response to RSV has incidental antibacterial effects. Using coordinated proteomics and metagenomics analysis we simultaneously analysed the microbiota and proteomes of the upper airway and determined direct antibacterial activity in airway secretions of RSV-infected children. Here, we report that the airway abundance of Streptococcus was higher in samples collected at the time of RSV infection compared with samples collected one month later. RSV infection is associated with neutrophil influx into the airway and degranulation and is marked by overexpression of proteins with known antibacterial activity including BPI, EPX, MPO and AZU1. Airway secretions of children infected with RSV, have significantly greater antibacterial activity compared to RSV-negative controls. This RSV-associated, neutrophil-mediated antibacterial response in the airway appears to act as a regulatory mechanism that modulates bacterial growth in the airways of RSV-infected children.

Sande, C. J., Njunge, J. M., Mwongeli Ngoi, J., Mutunga, M. N., Chege, T., Gicheru, E. T., Gardiner, E. M., Gwela, A., Green, C. A., Drysdale, S. B., Berkley, J. A., Nokes, D. J., Pollard, A. J.

Pages:2218, Volume:10, Edition:5/19/2019, Date,May-17

Link: https://www.ncbi.nlm.nih.gov/pubmed/31101811

Notes:Sande, Charles J|Njunge, James M|Mwongeli Ngoi, Joyce|Mutunga, Martin N|Chege, Timothy|Gicheru, Elijah T|Gardiner, Elizabeth M|Gwela, Agnes|Green, Christopher A|Drysdale, Simon B|Berkley, James A|Nokes, D James|Pollard, Andrew J|eng|Wellcome Trust/United Kingdom|WT105882MA/Wellcome Trust (Wellcome)/International|Research Support, Non-U.S. Gov’t|England|2019/05/19 06:00|Nat Commun. 2019 May 17;10(1):2218. doi: 10.1038/s41467-019-10222-z.

ISBN: 2041-1723 (Electronic)|2041-1723 (Linking) Permanent ID: PMC6525170 Accession Number: 31101811

Author Address: KEMRI-Wellcome Trust Research Programme, Bofa Rd, Kilifi, – P.O. Box 230 – 80108, Kenya. csande@kemri-wellcome.org.|Oxford Vaccine Group, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, Oxford, OX3 7LE, UK. csande@kemri-wellcome.org.|KEMRI-Wellcome Trust Research Programme, Bofa Rd, Kilifi, – P.O. Box 230 – 80108, Kenya.|Oxford Vaccine Group, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, Oxford, OX3 7LE, UK.|Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, OX3 7FZ, Oxford, UK.|The Childhood Acute Illness & Nutrition (CHAIN) Network, Nairobi, – P.O. Box 43640-00100, Kenya.|School of Life Sciences and Zeeman Institute (SBIDER), University of Warwick, CV4 7AL, Coventry, UK.

STATISTICS